Loading
A phase 1/2 trial of Ifinatamab deruxtecan, Durvalumab in small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) is a phase 1/2 interventional study registered as NCT06780137 by Merck Sharp & Dohme LLC, with 327 participants planned, started 2025-02-27 and due to reach its primary completion in 2029-04-27. Interventions recorded: Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/